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I.

INTRODUCTION

From families trying to make ends meet to a state government
working to balance its budget, rising health care costs pose a
significant and daunting public policy challenge. Minnesota
Governor Tim Pawlenty’s Health Cabinet estimates that health care
† Kevin Goodno, an attorney and the Commissioner of the Department of
Human Services for the State of Minnesota, was charged by Governor Pawlenty
with the development and operation of the Minnesota RxConnect program.
††
General Counsel to Minnesota Governor Tim Pawlenty.
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1

costs in Minnesota increase $70 each second. Every hour, health
care in Minnesota costs a quarter of a million dollars more than it
2
did last year.
The escalating cost of health care is one of the reasons
Minnesota faced a projected $4.2 billion budget shortfall when
3
Governor Pawlenty took office on January 6, 2003. The budget of
the Department of Human Services, which is one quarter of the
state budget, was projected to increase by 22% over the previous
4
biennium largely due to rising health care costs. In addition, the
state as an employer was experiencing a 17% increase in the cost of
5
providing health care insurance to its own state employees.
Besides the direct impacts on the state, increased health care
costs incurred by the private sector impact the state in indirect
ways. As employers are forced to spend more on non-taxable
health care benefits for their workers, they spend less on salaries,
which are taxable. This in turn negatively impacts the revenue the
state generates from income and sales taxes, making the budget
challenge even worse.
Despite all these pressures, Minnesota has consistently had one
6
of the lowest rates of uninsured individuals in the country. This
has been attributed to the generous state health care programs and
to the fact that more of Minnesota’s employers, as compared to
their counterparts in other states, provide health care coverage for
7
their employees. This is the good news. The bad news is that if
health care costs continue to escalate, state government and private
employers will be forced to reduce coverage, which will increase
the number of uninsured in the state.
In addition to appointing the Minnesota Citizens Forum on
1. State of Minnesota, Governor’s Health Cabinet: Minnesota Department of
Employee Relations, at http://maximumstrengthhealthcare.com (last visited Feb. 5,
2005).
2. Id.
3. Minnesota Department of Human Services, Office of Budget
Management, at http://www.dhs.state.mn.us (last visited Jan. 30, 2005).
4. Id.
5. Minnesota
Department
of
Employee
Relations,
at
http://www.doer.state.mn.us (last visited Feb. 5, 2005).
6. Minnesota Health Department, Minnesota’s Uninsured: Findings from the
2001 Health Access Survey, (April 2002), available at http://www.health.state.mn.us
(hereinafter Minnesota’s Uninsured); see also Minnesota Department of Health,
Health Economics Program Issue Brief: 2002 Minnesota Distribution of Insurance Coverage,
(April
2004),
available
at
http://www.health.state.mn.us/divs/hpsc/
hep/issbrief/2004-03.pdf.
7. Minnesota’s Uninsured, supra note 6.
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Health Care Costs to address the daunting task of controlling
8
health care costs, Governor Pawlenty directed his state agencies to
9
develop their own strategies to address health care costs. A result
of this directive was a variety of initiatives to control the high cost of
prescription medicines.
As advances in prescription medicines have improved length
and quality of life, a hugely disparate international pricing system
has evolved in which pharmaceutical companies charge wildly
different prices for the same product in different countries. The
cost for individuals, particularly seniors with no prescription
medicine coverage, has risen so significantly that it has too often
forced choices between buying medicines and meeting other basic
needs.
In the United States, about $160 billion is spent on
prescription medicines each year, with Minnesotans spending
10
about $3 billion. The costs of prescription medicines receive so
much attention in large part because, although prescription
medicine costs constitute only 10.5% of total health care spending,
they account for 23% of the total out-of-pocket costs that people
11
incur when purchasing health care. Minnesota has been a leader
in controlling prescription medicine costs. It has aggressively used
purchasing pools when possible, and encouraged the use of lower
cost, generic prescription medicines when appropriate.
Even with these efforts to control costs, prescription medicines
were still becoming too costly for many Minnesotans to afford.
12
Busloads of senior citizens headed north for Canada. Others used
13
Internet pharmacies, some of which were unsafe. The need for
lower cost prescription medicine alternatives and a desire to
protect the safety of Minnesotans who seek them caused Governor
Pawlenty, in September of 2003, to direct the Minnesota
Department of Human Services to examine the feasibility of
8. Minnesota Citizens Forum on Health Care Cost, available at
http://www.mncitizensforum.org (last updated Feb. 27, 2004).
9. Id.
10. Warren Wolfe, Modest Start for State Drug Sites, STAR TRIB., July 21, 2004,
available at www.startribune.com/viewers/story.php?template=a&story=4886132.
11. Donald L. Barlett & James B. Steele, Why We Pay So Much for Drugs, TIME,
Feb. 2, 2004, at 44, 47.
12. See, e.g., Rx Express, Mark Dayton, United States Senator, available at
http://dayton.senate.gov/issues/health/rx-express.cfm.
13. Press Release, Tim Pawlenty, Governor of Minnesota, Governor Pawlenty
Takes Action on Problem of Escalating Prescription Drug Costs (Sept. 24, 2003)
(on file with author).
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importing prescription medicines from Canada and other
14
international sources. He directed the Commissioner of Human
Services to examine methods to address the needs of Minnesota
state employees, the citizens served through the state’s public
15
assistance programs, and the state’s citizens at large.
In response to this directive, a three-phase plan was
16
developed. The plan called for the development of a website to
empower Minnesota consumers to purchase mail-order
prescription medicines for personal use from approved Canadian
pharmacies; the option for Minnesota state employees to
voluntarily obtain prescriptions for maintenance medications from
Canadian pharmacies; and the establishment of a pilot project that
allows Minnesotans to purchase Canadian prescription medicines
17
from their local pharmacies.
II. MINNESOTA RXCONNECT
On January 30, 2004, Minnesota RxConnect (RxConnect) was
launched, making Minnesota the first state in the nation to
establish a website to empower its citizens to purchase prescription
18
medicines from Canada. Consumer savings and safety were the
driving purposes for establishing RxConnect. Health and safety are
not served by Minnesotans foregoing needed prescription
medicines because they are too expensive. For more than a
decade, many Minnesotans have been physically crossing the
border into Canada to purchase needed prescription medicines,
19
often at the encouragement of elected officials. The growth of
Internet and mail-order pharmacies has increased Minnesotans’
access to prescription medicines from other countries. Various
estimates place the total sales of Canadian prescription medicines
14. Id.
15. Id.
16. Tim Pawlenty, Governor of Minnesota, Testimony to the Congressional
Prescription Drug Access Coalition hearing in Boston, MA (Oct. 28, 2003)
(transcript
available
at
http://www.governor.state.mn.us/Tpaw_View_DF_
Article.asp?artid=654).
17. Id.
18. Press Release, Tim Pawlenty, Governor of Minnesota, Governor Pawlenty
Unveils First-In-The-Nation Effort to Facilitate Purchase of Prescription Drugs
from Canada (Jan. 30, 2004) (on file with author).
19. Press Release, Mark Dayton, United States Senator, Dayton Uses First
Senate Speech to Press Congress and President To Make Prescription Drugs More
Affordable for Seniors (Feb. 26, 2001), available at http://www.dayton.senate.gov/
news/ details.cfm?id=229450&&.
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to the United States in a range between $600 million and $1 billion
20
RxConnect recognizes this reality and provides
a year.
Minnesotans with information on prescription medicines, safety,
and selected Canadian pharmacies.
Minnesota is not alone in its effort to provide information to
citizens who seek information on lower cost prescription
medicines. Although Minnesota’s RxConnect website may have
been the first state site to go online, other state and local
governments have quickly followed. Wisconsin, North Dakota,
Rhode Island, New Hampshire, as well as county and city
governments throughout the United States, have all initiated
21
prescription medicine programs for their residents. In expressing
the position of the U.S. Food and Drug Administration (FDA), FDA
Associate Commissioner of External Relations, Peter Pitts, claimed
that “illegal, unsafe importation presents the very real danger of
22
turning the Internet into the 21st century’s virtual drug cartel.”
William Hubbard, the FDA Associate Commissioner for Policy and
Planning, in a letter to Governor Pawlenty, specifically attacked
23
RxConnect as “unsafe, unsound, and ill-considered.”
The
criticisms from the FDA and other detractors of RxConnect have
centered on concerns about the legality of the website, the safety of
the prescription medicines and whether there are actual cost
savings to consumers.
III. RXCONNECT INFORMS AND PROTECTS MINNESOTA CITIZENS AND
DOES NOT VIOLATE FEDERAL LAW
States play a critical role in our system of government and have
traditionally served as the nation’s laboratory for innovative
programs that provide for the protection and general welfare of
their citizens. Although the federal government has authority,
within the limitations of the Constitution, to pass laws to govern the
country, in areas where Congress has not acted to require or
20. Christopher Rowland, Canada Threatens to Halt Shipments of Drugs to US,
BOSTON GLOBE, Nov. 11, 2004, (located at Boston Globe Archives, 2004-11-11).
21. Irakli Khodeli, Prescription Drug Importation Gains Momentum, STATE NEWS,
August 2004, at 14, 15.
22. Peter J. Pitts, Associate Commissioner for External Relations, FDA,
Remarks at the NCSL Health Leaders Seminar (Dec. 10, 2003), available at
http://www.ncsl.org/programs/health/pitts.htm.
23. Letter from William K. Hubbard, Associate Commissioner for Policy and
Planning, FDA, to Tim Pawlenty, Governor, Minnesota (Feb. 23, 2004), available at
http://www.fda.gov/oc/opacom/hottopics/importdrugs/pawlenty022304.html.
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prohibit an action, the states generally remain free to exercise their
24
authority.
Governor Pawlenty’s prescription medicine website reflects an
appropriate exercise of authority by the State of Minnesota.
RxConnect provides information to Minnesotans so that they can
make informed decisions in relation to their purchase of
25
prescription medicines. The state’s efforts to inspect participating
Canadian pharmacies fits within the state’s general role of actions
to inform the public about recommended safety measures for
pharmacies and a comparison to the measures used by pharmacies
licensed by the state. The information available on the RxConnect
website enhances the potential safety for citizens who choose to
26
purchase lower cost prescription medicines from Canada.
A. RxConnect Is Consistent with Federal Law
Although the FDA was quick to criticize and threaten
Governor Pawlenty and other state and local officials who created
programs to inform their citizens about the significant cost savings
27
on prescription medicines available in the Canadian market,
24. See U.S. CONST. amend. X (“The powers not delegated to the United
States by the Constitution, nor prohibited by it to the States, are reserved to the
States respectively, or to the people”).
25. RxConnect provides information about safe purchasing and use of
prescription drugs, cost-saving tips and links to assistance programs, instructions
for ordering medicine from participating pharmacies, and information on the
participating pharmacies and the selection process. Minnesota RxConnect, How to
Use This Site, at http://www.state.mn.us/cgi-bin/portal/mn/jsp/content.d
o?contentid=536901930&contenttype=EDITORIAL&hpage=true&agency=Rx (last
visited Jan. 28, 2005).
26. For example, RxConnect provides advice on how to properly use and
store prescription drugs and advice about shopping for drugs on the internet.
Minnesota
RxConnect,
Safety
First,
at
http://www.state.mn.us/cgibin/portal/mn/jsp/content.do?id=-536885275&agency=Rx (last visited Jan. 28,
2005).
27. See FDA, Importing Prescription Drugs, Letters to State and Local Officials,
available at http://www.fda.gov/oc/opacom/hottopics/importdrugs/ (last visited
Jan. 27, 2005). Recipients of the letters include: Minnesota Governor Tim
Pawlenty, Wisconsin Governor Jim Doyle, Illinois Governor Rod Blagojevich,
Rhode Island Governor Donald Carcieri, New Hampshire Governor Craig Benson,
Washington D.C. Mayor Anthony A. Williams, and Caldwell County North
Carolina administrator Bobby White. Springfield, Massachusetts and Birmingham,
Alabama have undertaken importation programs for their residents. The State of
Vermont is also currently suing the Secretary of the federal Department of Health
and Human Services in relation to the FDA’s refusal to allow Vermont to initiate a
pilot importation program. In Minnesota, Governor Pawlenty and Human
Services Commissioner Kevin Goodno have taken issue with the accuracy of
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Minnesota’s prescription medicine program is consistent with
federal law. RxConnect provides information to consumers so that
the consumer can make their own informed choices regarding
their health care.
Nothing in federal law prohibits states,
individuals, or any other entity from providing information or even
from advocating the importation of prescription medicines.
Moreover, RxConnect reflects Minnesota’s exercise of its
28
traditional power as a state to inform and protect its citizens.
29
These rights have not been preempted by federal law. As a result,
Minnesota’s program falls squarely within the protection of the
First Amendment and the protection of state authority granted by
30
the Tenth Amendment of the United States Constitution.
B. Importation Under the FDCA
31

The Federal Food, Drug, and Cosmetic Act (FDCA) governs
importation of prescription medicines in the United States. As to
importation of pharmaceutical products from foreign countries,
the FDCA distinguishes between importation of pharmaceutical
products that were manufactured in the United States and

assertions made by FDA officials and have provided specific responses to the
assertions made in the FDA letters. See Letter from Kevin Goodno, Commissioner,
Minnesota Department of Human Services, to William K. Hubbard, Associate
Commissioner for Policy and Planning, FDA, (Mar. 9, 2004) (on file with author).
28. States traditionally have the power to enact legislation to protect the
health and safety of their citizens. Medtronic, Inc. v. Lohr, 116 S. Ct. 2240, 2245
(1996) (quoting Hillsborough County v. Automated Med. Labs., Inc., 471 U.S.
707, 719, 105 S. Ct. 2371, 2378, 85 L. Ed.2d 714 (1985), Metro. Life Ins. Co. v.
Massachusetts, 471 U.S. 724, 756, 105 S. Ct. 2380, 2398 (1985)). These traditional
powers are called police powers. “[T]he police power of a state embraces
regulations designed to promote the public convenience or the general
prosperity, as well as regulations designed to promote the public health, the public
morals, or the public safety.” Chicago, B. & Q. Ry. Co. v. Illinois, 26 S. Ct. 341, 349
(1906).
29. Federal preemption requires that state law must give way when it conflicts
with or frustrates federal law. See U.S. CONST. art. VI cl. 2. “State law is preempted
when Congress expressly prohibits state regulation, when Congress implicitly
leaves no room for state involvement by pervasively occupying a field of regulation,
and when state law directly conflicts with federal law.” Chapman v. Lab One, 390
F.3d 620, 624 (8th Cir. 2004); see 16A AM. JUR. 2D Constitutional Law § 241.
30. See U.S. CONST. amend. I (“Congress shall make no law. . . abridging the
freedom of speech”); U.S. CONST. amend. X (“[t]he powers not delegated to the
United States by the Constitution, nor prohibited by it to the States, are reserved
to the States”).
31. 21 U.S.C. § 301 (2000).
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32

products that were manufactured in other countries. The FDCA
prohibits any importation into the United States of a prescription
33
medicine that was originally manufactured in the United States.
Prescription medicines that are initially manufactured within the
United States and later exported may be brought back into the
34
United States only by the product’s manufacturer. Thus, once
prescription medicines manufactured within the United States
leave the country, nobody except the manufacturer can import the
prescription medicine back into the country and into the stream of
commerce.
Prescription medicines manufactured in countries other than
the United States can be legally imported into the United States if
the medicines comply with the FDCA. It is not a violation of the
Act to import FDA-approved prescription medicines that were
manufactured outside of the United States if the product is
properly labeled in accordance with the FDCA and distributed with
35
a valid prescription. The FDA has taken the position that almost
all importation of prescription medicines manufactured outside of
36
the United States will violate the FDCA. The FDA asserts that in
order to be FDA-approved the imported medicines must comply
with all of the product-specific, manufacturer-specific, processspecific, and labeling-specific requirements established for the
manufacturer’s FDA application and approved by the FDA in
37
accordance with federal regulations. Under the FDA’s analysis,
any slight variation or technical deviation in the content or
packaging from the U.S. equivalent makes the product an
38
“unapproved” product.
32. See, e.g., 21 U.S.C. at § 381(d)(1).
33. Id.
34. Id.
35. See 21 U.S.C. §§ 355 (unapproved drugs), 352 (labeling requirements),
and 353(b)(1) (prescription drugs).
36. Letter from William K. Hubbard, Associate Commissioner for Policy and
Planning, FDA to Robert P. Lombardi, Esq., the Kullman firm (Feb. 12, 2003),
available at http://www.fda.gov/ora/import/kullman.htm.
37. Id. (citing 21 C.F.R. § 314.50 (2004)).
38. The significance underlying the differences between the importation
provisions is highlighted by the reality of the global manufacturing process for
prescription medicines. Currently, prescription medicines available in the United
States are manufactured around the globe. Lipitor, a popular cholesterollowering medicine manufactured by Pfizer, Inc., is manufactured in Ireland. See
Lipitor Product Information, available at http://www.lipitor.com/cwp/app
manager/lipitor/lipitorDesktop?_nfpb=true&_pageLabel=prescribingInformation
(last visited Feb. 5, 2005).
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Importation of prescription medicines in violation of the
39
A
FDCA, or the “causing thereof,” is prohibited by the Act.
violation of the Act, if enforced, can result in an administrative
warning, civil legal action for injunctive relief, seizure of product,
40
and in some cases, criminal prosecution.
The provisions of the FDCA prohibiting certain importation of
prescription medicines may give way to broader legalization of
importation programs. Congress has expressly recognized the
need to explore the safe importation of prescription medicines. In
2000, Congress made specific factual findings regarding access to
affordable prescription medicines in alternative markets:
(1) The cost of prescription drugs for Americans
continues to rise at an alarming rate.
(2) Millions of Americans, including Medicare
beneficiaries on fixed incomes, face a daily choice
between purchasing life-sustaining prescription drugs, or
paying for other necessities, such as food and housing.
(3) Many life-saving prescription drugs are available in
countries other than the United States at substantially
lower prices, even though such drugs were developed and
are approved for use by patients in the United States.
(4) Many Americans travel to other countries to purchase
prescription drugs because the medicines that they need
are unaffordable in the United States.
(5) Americans should be able to purchase medicines at
prices that are comparable to prices for such medicines in
other countries, but efforts to enable such purchases
should not endanger the gold standard for safety and
effectiveness that has been established and maintained in
41
the United States.
These congressional findings recognize the plight of millions
of Americans: they are struggling to afford costly prescription
medicine, they are already crossing borders to obtain their
medicines, and the need for appropriate safety protections in
relation to accessing affordable prescription medicines available in
other markets.
In 2000, Congress amended the FDCA to require the Secretary
39. See 21 U.S.C. § 331(a), (d), (t) (2000).
40. See 21 U.S.C. §§ 331-34, 336-37 (2000).
41. Medicine Equity and Drug Safety Act of 2000, H.R. 4461, 106th Cong. §
745(b) (2000); Pub. L. No. 106-387, § 745(b), 114 Stat. 1549 (2000).
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of Health and Human Services, in consultation with the United
States Trade Representative, to promulgate regulations permitting
pharmacists and wholesalers to import pharmaceutical products
42
covered by the FDCA. Under these new provisions, the Secretary
of Health and Human Services was required to develop safeguards
to ensure that imported products comply with key provisions of the
FDCA regarding safety and efficacy, and develop safeguards that
43
generally provide for the protection of the public. However, the
2000 amendments contained a provision that significantly
weakened the directive to the Secretary to create regulations:
“[t]his section shall become effective only if the Secretary
demonstrates to the Congress that the implementation of this
section will (1) pose no additional risk to the public’s health and
safety; and (2) result in a significant reduction in the cost of
44
covered products to the American consumer.”
Based on this
provision, the Secretary of Health and Human Services under both
the Clinton and Bush administrations has declined to make the
certification.
In 2003, Congress significantly amended this new provision.
The amendments specifically require the development of
regulations that permit the importation of prescription medicines
45
from Canada by pharmacists and wholesalers. Significantly, the
2003 amendments for the first time provide directives to the
Secretary of Health and Human Services in relation to importation
of prescription medicines by individuals for personal use:
Declarations. Congress declares that in the enforcement
against individuals of the prohibition of importation of
prescription drugs and devices, the Secretary should
(A) focus enforcement on cases in which the
importation by an individual poses a significant threat
to public health; and
(B) exercise discretion to permit individuals to make
such importations in circumstances in which
(i) the importation is clearly for personal use;
and
(ii) the prescription drug or device imported

42.
43.
44.
45.

21 U.S.C. § 384(a) (2000).
Id. § 384(b).
Id. § 384(l).
Id. § 384(b).
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does not appear to present an unreasonable risk
46
to the individual.
The Secretary can address personal use enforcement by either
providing for case-by-case waivers to individuals, or by regulation
47
on specific prescription medicines or a class of medicines. As to
prescription medicines imported from Canada, the amendment
provides that
the Secretary shall by regulation grant individuals a waiver
to permit individuals to import into the United States a
prescription drug that (A) is imported from a licensed
pharmacy for personal use by an individual, not for resale,
in quantities that do not exceed a 90-day supply; (B) is
accompanied by a copy of a valid prescription; (C) is
imported from Canada, from a seller registered with the
Secretary; (D) is a prescription drug approved by the
Secretary . . . ; (E) is in the form of a final finished dosage
that was manufactured in an establishment registered
48
under section 360.
The Secretary can also impose other conditions deemed necessary
49
to ensure public safety.
The 2003 amendments continue the condition that the
provisions become effective only if the Secretary certifies that the
50
provision will “pose no additional risk of harm.”
Congress
suggested the Secretary of Health and Human Services should
conduct a study on the importation of drugs under the 2003
51
amendments to the FDCA. If the Secretary submits a certification
report on the study to Congress within twelve to eighteen months
from the date of enactment stating that the benefits do not
outweigh the detrimental effects of the amendments, they will
52
cease to have effect. In December of 2004, the Secretary issued
his Report on Prescription Drug Importation to Congress finding
that the benefits of drug importation did not outweigh the risks of
53
potential harm to the American public.
At this point, unless
Congress acts to establish a safe importation program, further
46. Id. § 384(j)(1)(1).
47. Id. § 384(j)(2).
48. Id. § 384(j)(3).
49. Id. § 384(j)(3)(F).
50. Id. § 384(l).
51. Id. § 384(l)(2)(A).
52. Id.
53. Report on Prescription Drug Importation, HHS Task Force on Drug
Importation, United States Department of Health and Human Services, December 2004.
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54

action by the FDA to establish such program appears unlikely.
C. FDA’s Current Personal Use Policy

Notwithstanding the 2003 amendment to the FDCA, relating
to the possible development of regulations or waiver procedures
for the importation of prescription medicines for personal use, the
FDA has had a longstanding practice of not enforcing the FDCA’s
importation prohibitions against individuals who are importing
small amounts of prescription medicines for personal use. The
FDA has expressly recognized in its Regulatory Procedures Manual
55
an exemption on enforcement for personal importations. The
56
general guidance in the Regulatory Procedures Manual provides,
in relevant part:
FDA personnel may use their discretion to allow entry of
shipments of violative FDA regulated products when the
quantity and purpose are clearly for personal use, and the
product does not present an unreasonable risk to the
user. Even though all products that appear to be in
violation of statutes administered by FDA are subject to
refusal, FDA personnel may use their discretion to
examine the background, risk, and purpose of the
product before making a final decision. Although FDA
may use discretion to allow admission of certain violative
items, this should not be interpreted as a license to
individuals to bring in such shipments. . . . Commercial
and promotional shipments are not subject to this
57
guidance.
The Regulatory Procedures Manual provides that FDA
personnel should not examine personal baggage (a function to be
54. There continues to be interest in Congress for establishing a prescription
medicine importation program. On February 16, 2005, Governor Pawlenty testified
about Minnesota’s efforts in relation to lowering the costs of prescription medicines
before the Senate Committee on Health, Education, Labor, and Pensions. Governor
Pawlenty’s
testimony
is
available
at
http://www.governor.state.mn.us/
tpaw_view_article.asp?artid=1260.
55. See OFFICE OF REGULATORY AFFAIRS, U.S. FOOD AND DRUG ADMIN.,
REGULATORY PROCEDURES MANUAL: Ch. 9 IMPORT OPERATIONS/ACTIONS (2004 ed.),
available
at
http://www.fda.gov/ora/compliance_ref/rpm_new2/ch9/
default.htm.
56. See id. The personal importation provisions are contained in the
Regulatory Procedures Manual (RPM), Chapter 9, in the subchapter on Coverage
of Personal Importations. As of January 2005, Chapter 9 of the RPM, which
addresses import operations/actions, was being revised.
57. Id.
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left to the U.S. Customs Service) and that the guidance in relation
to personal importations is intended to apply both to personal mail
58
shipments and personal baggage.
As a greater number of Americans have looked to Canada for
relief from high prescription medicine prices and the importation
issues have grown in national prominence, the FDA has issued
several informational letters asserting a narrow application of the
59
The FDA has publicly asserted that the
personal-use policy.
discretion provided by the personal-use policy is intended to apply
only to allow for “medical treatments sought by individuals that are
not otherwise available in the United States” and not in scenarios
where the FDA-approved medicines are available more cheaply in
60
the foreign country.
The guidance identifies circumstances in which the FDA may
consider exercising enforcement discretion and refrain from taking
legal action against illegally imported drugs. Those circumstances
are as follows:
1) the intended use [of the drug] is unapproved and for a
serious condition for which effective treatment may not be
available domestically either through commercial or
clinical means;
2) there is no known commercialization or promotion to
persons residing in the U.S. by those involved in the
distribution of the product at issue;
3) the product is considered not to represent an
unreasonable risk; and
4) the individual seeking to import the product affirms in
writing that it is for the patient’s own use (generally not
more than a 3 month supply) and provides the name and
address of the doctor licensed in the U.S. responsible for
his or her treatment with the product, or provides
evidence that the product is for the continuation of a
61
treatment begun in a foreign country.
58.
59.

Id.
See, e.g., OFFICE OF REGULATORY AFFAIRS, U.S. FOOD AND DRUG ADMIN.,
INFORMATION ON IMPORTATION OF DRUGS PREPARED BY THE DIVISION OF IMPORT
OPERATIONS
AND
POLICY,
FDA
(Apr.
3,
1998),
available
at
http://www.fda.gov/ora/import/pipinfo.htm.
60. Id.
61. OFFICE OF REGULATORY AFFAIRS, U.S. FOOD AND DRUG ADMIN., IMPORTATION
PRESCRIPTION
MEDICINES/DRUGS,
TRAVEL
ALERT,
available
at
OF
http://www.fda.gov/ora/import/traveler_alert.htm (last visited Feb. 5, 2005)
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Although the FDA has recently gone out of its way to
emphasize that it believes it has a right to take enforcement action
against individuals importing prescription medicines available in
the United States for their personal use, the FDA has generally not
62
pursued such action against individuals. Recently, however, the
FDA took action to seize a number of personal mail shipments of
prescription medicines that had been ordered by seniors in
Minnesota, Wisconsin, and other states through a Canadian
63
Internet pharmacy.
When the FDA’s action resulted in angry
outcries from senior citizen advocacy groups and federal senators
from Minnesota and Wisconsin, the FDA released the shipments to
64
the individuals.
D. FDA Enforcement: The Rx Depot, Inc. Case
Although legal action against individuals has not been pursued
by the federal government, the FDA has pursued legal action
against a private company in relation to importation of prescription
medicines. In United States v. Rx Depot, Inc., the United States
brought a legal action against Rx Depot, Inc., affiliated companies,
and individual officers of Rx Depot to enjoin alleged violations of
65
the FDCA. Rx Depot sold U.S. customers prescription medicines
66
The customers brought
ordered from a Canadian pharmacy.
their prescriptions, required medical forms, and payment
information directly to Rx Depot, which transmitted the
67
information to a participating Canadian pharmacy.
Rx Depot
received a direct commission on each sale filled by the Canadian
68
pharmacy. The court found that Rx Depot essentially worked as a
69
commissioned sales force for the Canadian pharmacy.
70
In issuing the preliminary injunction, the court found that
(emphasis in original).
62. See, e.g., Letter from William K. Hubbard, FDA Associate Commissioner
for Policy and Planning, to Robert P. Lombardi, Esq., The Kullman Firm (Feb. 12,
2003), available at http://www.fda.gov/ora/import/kullman.htm.
63. Julie Appleby, Drugs from Canada Seized, USA TODAY, Sept. 17, 2004, at 5B.
64. See Drug Importation; Wisconsin Senators Ask FDA Why it Intercepted Drugs from
Canada, HEALTH & MED. WK., Oct. 4, 2004, at 455.
65. 290 F. Supp. 2d 1238 (N.D. Okla. 2003).
66. Id. at 1240-41.
67. Id.
68. Id. at 1241.
69. Id.
70. Id. at 1250. Rx Depot’s motion to stay the preliminary injunction
imposed by the court was denied in United States v. Rx Depot, Inc., 297 F. Supp. 2d
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the United States was likely to prevail on its claims that Rx Depot’s
role in the transaction “caused” the importation of prescription
medicines originally manufactured in the United States, as well as
the importation of new unapproved medicines manufactured in
71
foreign countries in violation of the FDCA.
E. Minnesota’s RxConnect Program Does Not Violate the FDCA
The FDA has been quick to criticize state and local officials
who take action to inform their citizens about the availability and
72
affordability of prescription medicines from Canada.
Nevertheless, to date, the FDA has not attempted to enjoin any of
the state or local government entities that have set up programs to
inform citizens regarding Canadian prescription medicines.
Even if challenged by the FDA, RxConnect does not violate the
FDCA. RxConnect is specifically set up to provide information to
Minnesotans and through that information help protect the safety
of Minnesotans who choose to pursue a purchase of prescription
medicines from Canada. Although an individual can obtain
information and download order forms from the website, the state
of Minnesota does not participate in any manner in the decision
made by the consumer or in the transaction conducted with the
Canadian pharmacy. The state also does not receive any type of
compensation or benefit from the pharmacy or the consumer.
Instead, the RxConnect website merely provides a comparison
of prescription medicine costs in the United States with costs in
Canada, information on the possibility of cheaper generic
medicines in the United States, and safety tips regarding
73
prescription medicines. The information provided on the website
makes it clear that the purpose of the program is to inform
Minnesotans, and “to provide Minnesotans information on issues
related to prescription medicine, safety and cost-saving tips, and
programs to help low-income Minnesotans pay for prescription
74
medications.” The RxConnect website also provides Minnesotans
1306 (N.D. Okla. 2003).
71. Rx Depot, 290 F. Supp. 2d at 1247.
72. See, e.g., Letter from William K. Hubbard, Associate Commissioner for
Policy and Planning, FDA, to Tim Pawlenty, Governor, State of Minnesota (Feb.
23, 2004) (on file with author).
73. See Minnesota RxConnect Online, at http://www.state.mn.us/cgibin/portal/mn/jsp/home.do?agency=Rx (last modified Jan. 11, 2005).
74. See Minnesota RxConnect Online, at http://www.state.mn.us/cgibin/portal/mn/jsp/content.do?id=-536885395&agency=Rx (last modified Jan. 11,
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with information about, and the identity of, pharmacies that have
been visited by Minnesota officials and information regarding the
safety standards used by the four pharmacies featured on the
75
website.
Individual consumers ultimately decide whether it is in their
interests to purchase their prescription medicines from Canada.
Given RxConnect’s public safety and information functions, there
is no legal basis to conclude Minnesota has violated or “caused” a
76
violation of the FDCA.
The state is no more involved in the
transaction than any other public interest group or media outlet
that provides information to the public concerning prescription
medicines.
Moreover, a conclusion that RxConnect violated the FDCA
would implicate important constitutional mandates. First, the state,
acting through its public officials, has the right to free speech—
especially where such speech bears directly on matters of public
77
policy and the safety of citizens. State officials could obviously
share any of the information contained on RxConnect orally, which
includes providing information about the pharmacies that are
willing to take orders from Minnesotans. The fact that a website is
used as the medium for communication rather than oral
communication does not change the nature of the speech.
The key feature of RxConnect is the state’s role in visiting
Canadian pharmacies, reviewing their safety protocols in
comparison with state pharmacy standards and discussing
procedures to provide enhanced safety in relation to the
78
importation of prescription medicines. It is well documented that
before Minnesota undertook these functions, many Minnesotans
were already crossing the border, either physically or electronically,
to purchase necessary prescription medicines. The need for
additional information and protection was clear. By providing
RxConnect, Minnesota helps to ensure that its citizens who chose
to purchase medicines from Canada, have a resource available for
making an informed decision.
2005).
75. Id.
76. See 21 U.S.C. § 301 (2000).
77. See U.S. CONST. amend. I.
78. See Minnesota RxConnect Online, at http://www.state.mn.us/cgibin/portal/mn/jsp/content.do?contentid=536902091&contenttype=EDITORIAL
&subchannel=null&sc3=null&sc2=null&id=-536885147&agency=Rx
(detailing
pharmacy screening criteria) (last modified Jan. 11, 2005).
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Finally, even assuming that the applicable provisions of the
FDCA reflect Congress’ valid exercise of authority under the
79
Commerce Clause, the scope of the FDCA must be interpreted in
light of the Tenth Amendment’s reservation of authority to the
80
states. Although Congress has the authority to regulate foreign
trade, RxConnect does not in any manner negate Congress’
authority to regulate trade, the regulatory structure established by
the FDCA, or the FDA’s authority to enforce the FDCA.
Nothing in the FDCA prohibits states from traveling to foreign
countries to review the safety procedures used by foreign
81
pharmacies. Similarly, there is no prohibition against states, or
anyone else, providing information to the public as to the safety
standards used by foreign pharmacies or negotiating with such
82
pharmacies for safer, more effective practices.
Without such a
prohibition under the Constitution or the FDCA, such power is
83
reserved to the states and to the citizens. That the information
and efforts of the states or citizens results in more individuals
choosing to import prescription medicines from other countries in
a manner that the FDA believes violates the FDCA, and which the
FDA may or may not choose to enforce against the individual, does
not alter the result.
IV. RXCONNECT ENHANCES THE SAFETY OF PRESCRIPTION
MEDICINES ORDERED FROM CANADA
The FDA’s safety concerns revolve around the operation of the
mail-order pharmacies and the safety of the prescription
84
medicines. The safety issues related to the pharmacies range from
allegations of poor operating practices to outright criminal
85
activity. The FDA has been at the forefront of the warnings about
79. See U.S. CONST. art. I, § 8.
80. See U.S. CONST. amend. X.
81. See 21 U.S.C. § 301 (2000).
82. See id.
83. See U.S. CONST. amend. X (“The powers not delegated to the United
States by the Constitution, nor prohibited by it to the States, are reserved to the
States respectively, or to the People.”).
84. Letter from William K. Hubbard, Associate Commissioner for Policy and
Planning, FDA, to Tim Pawlenty, Governor, State of Minnesota (Feb. 23, 2004)
(on file with author).
85. See id.; see also Canadian Prescription Drug Re-importation: Is There a Safety
Issue?: Hearing Before the House Committee on Government Reform, Subcommittee on
Human Rights and Wellness, 108th Cong. (June 12, 2003) (statement of William K.
Hubbard, Associate Commissioner for Policy and Planning, FDA), available at
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the safety of mail-order pharmacies. William Hubbard has argued
that the FDA does not “know of people getting sick or dying yet,
86
but people are at risk.” In his testimony to Congress, Hubbard
outlined his agency’s specific concerns regarding the safety of
prescription medicines ordered from Canada, primarily that the
product could be expired, contaminated, counterfeit, wrong, or
87
sub-potent.
In addition, the product could be of an incorrect
dosage, lack an English language label, lack proper directions, or
88
have experienced degradation due to improper handling.
Although warning of the dangers of Canadian mail-order
prescription medicines, Pitts has admitted that “Canadian drugs are
safe. If you walk into a pharmacy in Windsor, Ontario, and have a
prescription filled by a real pharmacist—the drugs you receive will
89
be both safe and effective.”
RxConnect offers Minnesotans a safe alternative to border
crossings and unknown, unregulated international websites. The
guidelines established for RxConnect and the process followed to
select Canadian pharmacies and to limit the prescription medicines
listed on RxConnect were rigorous and established with a focus on
making certain that consumers are receiving prescription
medicines approved for Canada from a real pharmacist—in other
words, prescription medicines that are safe and effective. In
launching RxConnect the single most important factor in
providing for consumer safety and addressing the concerns of the
90
FDA was choosing the participating Canadian pharmacies.
A. Pharmacies Listed on RxConnect are Inspected and Licensed
In November of 2003, the Minnesota Department of Human
Services (DHS) developed a request for responses: a document that
http://reform.house.gov/UploadedFiles/Hubbard%20Testimony%206-12-03.pdf
[hereinafter Re-importation Hearing]; Peter J. Pitts, Associate Commissioner for
External Relations, FDA, Prescription Drugs: Latest News, Latest Views, Remarks at the
National Conference of State Legislatures, Health Leaders Seminar (Dec. 10,
2003), available at http://www.ncsl.org/programs/health/pitts.htm [hereinafter
Pitts].
86. Warren Wolfe, Modest Start for State Drug Sales, STAR TRIBUNE,
(Minneapolis, St. Paul), July 21, 2004 at A1, available at 2004 WL 83076194 at *1.
87. Re-importation Hearing, supra note 85.
88. Id.
89. Pitts, supra note 85.
90. See Letter from Kevin Goodno, Commissioner, Minnesota Department of
Human Services, to William K. Hubbard, Associate Commissioner for Policy and
Planning, FDA (Mar. 9, 2004) (on file with author).
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requested responses to a series of questions from identified
Canadian mail-order pharmacies. The minimum requirements
were that the responder: was licensed to do business as a pharmacy
in the Canadian province in which it was located; had been
accredited or was eligible for accreditation by the Internet and
Mail-order Pharmacy Accreditation Commission and/or be a
member of the Canadian International Pharmacy Association; and
that all health care professionals employed by or under contract
with the responder, including pharmacists and physicians, have the
91
appropriate professional license.
The pharmacies were also asked to present detailed
information concerning their business experience, staff, facilities,
prescription medicine supply sources, prescription-filling process,
92
and other policies and procedures. DHS received twenty-seven
responses that were ranked based on the evaluation of their
93
responses. In addition, the following were considered:
1.
One responder was excluded from further
consideration because it was not a pharmacy but operated
a website affiliated with a pharmacy.
2. Some responders were excluded because they did not
operate at one location. Instead, a prescription ordered
from their websites might be routed to one of several or
even many pharmacies for actual filling.
3. Some responders were excluded because of their
relatively remote locations. For example, one pharmacy is
located approximately two hours away from Winnipeg.
Minnesota Board of Pharmacy Surveyors felt that a
minimum of three or four hours should be spent at each
facility. Therefore, driving to and from the more remote
94
locations was not an option.
95
Nine pharmacies were chosen for site visits.
The DHS
Pharmacy Program Manager and two Board of Pharmacy surveyors,
91. Request for Responses: Canadian Pharmacies, Minnesota Department of
Human Services, Health Care Administration (Dec. 2003) (on file with author).
92. Id.
93. Undated internal memorandum from Cody Wiberg, Pharmacy Program
Manager, Minnesota Department of Human Services, to Kevin Goodno,
Commissioner, Minnesota Department of Human Services (on file with author).
94. Id.
95. Report on the survey of Canadian pharmacies, from Cody Wiberg,
Pharmacy Program Manager, Minnesota Department of Human Services, to Kevin
Goodno, Commissioner, Minnesota Department of Human Services (June 21,
2004) (on file with author).
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all Minnesota licensed pharmacists, visited eight of the nine
96
The ninth
pharmacies initially selected for further review.
pharmacy selected for additional review was unable to be reached
for a site visit. The team considered the following when visiting the
facilities:
1. Quality of the facilities. The physical condition of the
facilities was considered, including the “[l]ighting, [the]
presence of a thermometer in medication refrigerators,
adequate space for the number of staff on duty, general
97
upkeep of facilities” and additional factors.
2. Operational procedures. The workflow, presence of
appropriate safety checks and adequate monitoring of
98
non-professional staff by pharmacists were reviewed.
3.
Source of prescription medicine.
Prescription
medicine packages were randomly checked for presence
of labeling that indicated the products had been approved
99
for use in Canada.
4. Answers to questions. Questions were posed to staff
about: “shipping and returns policies, procedures for
counseling patients on proper use of medications, the
role of Canadian physicians in the process, adequacy of
prescription [medicine] supply, source of prescription
100
medicines dispensed and other issues.”
5. Evidence of Licensure. Evidence that the pharmacy
and pharmacists were appropriately licensed by the
101
province in which the pharmacy is located.
Based on the recommendations of the inspection team, two
pharmacies were initially selected to participate in the Minnesota
102
program.
Both of these pharmacies appeared to operate in an
103
Two additional
efficient, safe, and professional manner.
pharmacies were added to the program in June 2004 after a similar
selection process was followed.

96. Id.
97. Undated internal memorandum from Cody Wiberg, Pharmacy Program
Manager, Minnesota Department of Human Services, to Kevin Goodno,
Commissioner, Minnesota Department of Human Services (on file with author).
98. Id.
99. Id.
100. Id.
101. Id.
102. Id.
103. Id.

http://open.mitchellhamline.edu/wmlr/vol31/iss3/2

20

Goodno and Janisch: Minnesota: Leading the Way on Canadian Prescription Medicine Impo
2GOODNOJANISCH.DOC

2005]

3/13/2005 3:01:05 PM

CANADIAN PRESCRIPTION MEDICINE IMPORTATION

831

To support the FDA position that the Canadian mail-order
pharmacies themselves were unsafe, Hubbard cited Minnesota’s
104
report on its site inspections of Canadian pharmacies.
Hubbard
noted that the report listed “dozens of safety problems” with the
105
pharmacies inspected. However, Hubbard’s characterization that
the report proved that ordering prescription medicines from
106
Canada is unsafe was inaccurate.
In a letter to Hubbard,
Minnesota DHS Commissioner Kevin Goodno responded to
Hubbard’s contentions by noting that Hubbard had made “at least
eight clear misstatements of fact regarding [the Minnesota] site
107
Each misstatement exaggerated either the
visit findings.”
breadth or the severity of the deficiencies found by [the inspectors]
108
in [their] site inspections of the Canadian pharmacies.”
Of the
specific findings from these visits, most did not relate to the two
109
pharmacies chosen for inclusion in the program.
Further,
“[s]ome of the findings that were characterized as dangerous
practices in [Hubbard’s] letter [are] commonly [cited] during
110
inspections of local, U.S. pharmacies.”
Most of the safety
problems identified in the Minnesota report “would normally be
handled with a finding and order to correct—not by shutting down
111
the pharmacy.”
Of the two initial pharmacies selected, there were items
identified by the inspectors for improvement. For the first
pharmacy selected, two issues were identified: (1) inadequate
lighting and (2) the failure of one of the pharmacists to record the
112
drug’s Drug Identification Number (DIN). Although the lighting
was adequate in most work areas it did not meet Minnesota
standards. However, “new lighting was being installed the day the
113
surveyors were visiting.” Also, the surveyors recommended to the
104. Letter from William K. Hubbard, Associate Commissioner for Policy and
Planning, FDA, to Tim Pawlenty, Governor, State of Minnesota (Feb. 23, 2004)
(on file with author).
105. Id.
106. See Letter from Kevin Goodno, Commissioner, Minnesota Department of
Human Services, to William K. Hubbard, Associate Commissioner for Policy and
Planning, FDA (Mar. 9, 2004) (on file with author).
107. Id.
108. Id.
109. Id.
110. Id.
111. Id.
112. Id.
113. Id.
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Canadian pharmacists that the DIN, Canada’s equivalent to the
National Drug Code (NDC) used in the United States, be written
114
on the paper prescription when doing the final check.
One
pharmacist at the pharmacy chose not to follow this procedure
because he felt it was unnecessary; however, Minnesota pharmacists
are not required by Minnesota law to write a drug’s NDC on a
115
prescription when it is being checked.
Accordingly, such a
requirement would hold the Canadian pharmacists to a “higher
116
standard than that for Minnesota pharmacists.”
The second pharmacy selected had three issues of concern
identified. Like the first pharmacy, its lighting did not meet
Minnesota standards but the pharmacy “upgraded its lighting prior
117
to the launch of RxConnect.” A follow-up inspection in July 2004
revealed that the lighting at this pharmacy now exceeds
118
Minnesota’s standard.
The pharmacy “also had a practice of
forwarding only the electronic health information transcribed into
its computer system to the Canadian physician, and the surveyors
recommended that both the original information and the
transcribed electronic information be forwarded for review by the
119
physician.” This policy was also subsequently changed. Finally, at
the request of the inspectors, the pharmacy changed its computer
system to default to “allergies unknown” rather than “no allergies”
120
when a customer did not provide allergy information.
All the issues of concern identified by the inspectors were
addressed before RxConnect was launched. The Minnesota
inspections did reveal that significant differences do exist among
Canadian Internet pharmacies regarding the quality of their
respective facilities and the safety standards followed in their
operations. However, contrary to the representations of the FDA,
the inspections showed that there are both high quality pharmacies
and lower quality pharmacies operating in Canada. These findings
114. Id.
115. Id.
116. Id.
117. Id.
118. Report on the survey of Canadian pharmacies, from Cody Wiberg,
Pharmacy Program Manager, Minnesota Department of Human Services, to Kevin
Goodno, Commissioner, Minnesota Department of Human Services (June 21,
2004) (on file with author).
119. Letter from Kevin Goodno, Commissioner, Minnesota Department of
Human Services, to William K. Hubbard, Associate Commissioner for Policy and
Planning, FDA (Mar. 9, 2004) (on file with author).
120. Id.
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actually support Governor Pawlenty’s contention that RxConnect is
necessary to protect the safety of Minnesotans who choose to
purchase prescription medicines from Canada.
In addition to FDA concerns, the Minnesota Pharmacists
Association raised concerns that RxConnect would affect patient
safety because it would result in the patient receiving
uncoordinated medical care from more than one health care
121
provider.
This not only adds inefficiency to patient care, but
could also result in harm to the patient if prescribed therapies are
not compatible.
This fragmentation of therapy is a real concern not only in
ordering prescription medicines from Canada, but in receiving
health care services in the United States—it is not a problem
unique to ordering prescription medicines from Canada. To
minimize the potential negative consequences of therapy
fragmentation, the participating pharmacies also practice the
following procedures: (1) The initial order placed by an American
patient must include a valid U.S. prescription and a health profile
of the patient; (2) The forms submitted by the patient are reviewed
once received to make certain they are complete; (3) The
prescription and health profile are forwarded to a Canadian doctor
for review; (4) If the doctor agrees with the prescription, the doctor
writes a Canadian prescription; (5) The forms and the Canadian
prescription are then reviewed by a Canadian pharmacist who only
122
fills the prescription if everything is in order.
In addition to meeting the selection criteria and the required
procedures outlined above, RxConnect pharmacies agreed to the
following:
1. The pharmacy and all its healthcare professionals must
maintain licensure in good standing in the province in
123
which it is located.
2. The pharmacy must follow all applicable Canadian

121. Press Release, Minnesota Pharmacists Association, Minnesota Pharmacists
Concerned about Governor Pawlenty’s Drug Importation Website (Jan. 30, 2004)
(on file with author).
122. Report on the survey of Canadian pharmacies, from Cody Wiberg,
Pharmacy Program Manager, Minnesota Department of Human Services, to Kevin
Goodno, Commissioner, Minnesota Department of Human Services (June 21,
2004) (on file with author).
123. Agreement between the Minnesota Department of Human Services and
the pharmacies selected for inclusion in RxConnect, at 4 (on file with author).
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124

laws.
3. All orders received must include a prescription from a
United States physician if the laws of Minnesota require a
125
prescription.
4. The pharmacy must ship no more than a ninety-day
supply of medicine, or an amount not to exceed the
126
prescribed amount for personal use to the patient.
5. To the extent possible, the pharmacy must ship the
ordered
prescription
medicine
in
unopened
127
manufacturer’s containers.
6. The pharmacy must not fill any order if it is indicated
128
that the prescription was being filled for the first time.
129
7. The pharmacy must provide periodic reports to DHS.
8. The pharmacy must allow unannounced site visits by
Minnesota inspectors to assure compliance with the
130
program requirements.
9. The pharmacy must only sell prescription medicines
that are approved by the government of Canada for sale in
131
Canada.
In establishing RxConnect Governor Pawlenty was not willing
to compromise patient safety for the sake of low cost prescription
medicines. Accordingly, the selection process did not factor in
potential price savings to consumers when selecting the Canadian
pharmacies. Through RxConnect, Minnesota consumers who wish
to purchase prescription medicines from Canada have the added
safety of knowing that the listed pharmacies are licensed under the
laws of Canada and have been inspected by Minnesota state officials
who found that they employ licensed professionals, follow good
operating procedures, and operate from quality facilities. In short,
the RxConnect pharmacies are “real” pharmacies with “real”
pharmacists filling the prescriptions with safe and effective
prescription medicines.

124.
125.
126.
127.
128.
129.
130.
131.

Id. at 3.
Id. at 2.
Id.
Id.
Id.
Id. at 4.
Id. at 3.
Id. at 2.
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B. Prescription Medicines Listed on RxConnect are Limited for Safety
In addition to the safety of the pharmacies listed on
RxConnect, the safety of the prescription medicines themselves was
carefully considered in establishing RxConnect. The United States
General Accounting Office (GAO) investigated Internet
pharmacies by attempting to place orders for thirteen different
prescription medicines from sixty-eight different Internet
pharmacies that were located in the United States, Canada, and
132
other foreign countries.
The investigation found that all eighteen Canadian
pharmacies required prescriptions from the patient’s physician,
which was not true for twenty-four of the twenty-nine United States
pharmacies and all twenty-one of the non-Canadian, foreign
133
pharmacies.
The report further concluded that of the
prescription medicines ordered from Canada, sixteen of the
eighteen samples were reported by the manufacturers to be
134
unapproved for sale in the United States. “However, the samples
were all found to be comparable in chemical composition to the
135
products . . . ordered.” In other words, the samples ordered from
Canada were not sub-potent, contaminated, counterfeit, the wrong
product, or degraded, but they were largely considered
136
unapproved because of labeling and packaging. For example, as
mentioned earlier, a prescription medicine can be characterized as
unapproved for sale in the United States even if the chemical
composition has been approved for use in the United States, it was
manufactured in an FDA approved facility, and it was packaged to
FDA standards simply because it has a Canadian label on it that
meets Canadian standards, but does not meet FDA standards.
To further protect safety, not all available prescription
medicines were included in RxConnect. For example, of the
thirteen different prescription medicines that the GAO attempted
to purchase during its investigation, RxConnect excludes eight of

132. Internet Pharmacies Some Pose Safety Risks for Consumers and are Unreliable in
Their Business Practices: Testimony before the Permanent Subcommittee on Investigations,
Committee on Governmental Affairs, U.S. Senate (June 17, 2004), available at
http://www.gao.gov/new.items/d04888t.pdf (Testimony of Marcia Crosse,
Director, Health Care—Public Health and Military Health Care Issues).
133. Id. at 9.
134. Id. at 16.
135. Id.
136. Id.
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137

them for various safety reasons.
The medications listed on
138
RxConnect are primarily those meant to treat chronic conditions.
Some prescription medicines listed are sometimes taken for acute
conditions, but they are sometimes taken on a chronic basis as well,
for example, some antibiotics are taken for extended periods of
139
time for acne.
The selected pharmacies have agreed not to ship
prescription medicines to United States customers if it is clear that
140
the prescription medicines are meant to treat acute conditions.
The list of prescription medicines included was further limited
because the state did not include those prescription medicines that
were:
1.
Controlled substances such as narcotics,
benzodiazepines (Valium and related), barbiturates,
anabolic steroids, amphetamines, etc.
Reputable
Canadian pharmacies such as those selected for affiliation
141
with RxConnect will not ship controlled substances.
2. Medications with special handling requirements such
142
as those needing refrigeration.
3. Medications for which there is not an FDA-approved
equivalent in the United States (such as those prescription
medicines that are either available generically in Canada,
but are not available generically in the United States, or,
those prescription medicines available in Canada that are
143
not available at all in the United States).
4. Medications that contain a level of active ingredient
different in the United States version than in the
Canadian version. For example, the Canadian version of
Allegra 24 Hour contains less fexofenadine, an
antihistamine, than the United States version and is not
144
listed on RxConnect.

137. Compare id. at 3, with Medicine Search, Minnesota RxConnect, available at
http://rxconnect.dhs.state.mn.us/Medicines.aspx (last visited Feb. 14, 2005)
(comparing prescription medicines ordered in GAO investigation and those listed
on MinnesotaRxConnect.com).
138. Internal Memorandum from Cody Wiberg, Pharmacy Program Manager
Minnesota Department of Human Services, to Kevin Goodno, Commissioner,
Minnesota Department of Human Services (on file with author).
139. Id.
140. Id.
141. Id.
142. Id.
143. Id.
144. Id.
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Unlike some states that have pursued similar programs to
RxConnect that have linked their websites directly to Canadian
145
pharmacies, RxConnect does not use direct links, so the state can
control all the information provided on the website regarding the
participating pharmacies, the prescription medicines offered, and
pricing. This allows the state to control for content and also to
control for compliance with the program requirements.
By restricting the prescription medicines included in
RxConnect, controlling the information listed on RxConnect, and
limiting RxConnect to prescription medicines that are approved
for use in Canada or the United States, RxConnect adds an
additional layer of protection for Minnesota consumers who want
to purchase safe and effective prescription medicines from Canada.
C. Some Prescription Medicines Cost Less in Canada
The perception of many is that all prescription medicines
purchased from Canada are less expensive than the comparable
product offered in the United States. This is clearly not true.
Likewise, some would have you believe that any savings a consumer
would see in Canada is negligible or can easily be offset through
use of generics or therapy modification. For example, sometimes
consumers can reduce their prescription medicine costs by
substituting brand name prescription medicines for generics, overthe-counter, or lower dosage medicines. This may work in some
cases, but not in all cases.
As a rule of thumb, brand name prescription medicines are
cheaper in Canada than the United States; generic prescription
medicines are less expensive in the United States than Canada;
and, United States generic prescription medicines, when available,
are less expensive than either the brand name prescription
medicines or the Canadian generics. This rule of thumb has
exceptions. For example, the generic prescription medicine
tamoxifen, which is used in the treatment of breast cancer, is less
expensive when purchased from the Canadian pharmacies
affiliated with RxConnect. A consumer can purchase sixty ten145. See, e.g., State of North Dakota website, at http://www.govenor
.state.nd.us; State of New Hampshire website, at http://www.state.nh.us/governor
/prescription-drug.html (last visited Mar. 5, 2005). See generally Congressman Gil
Gutknecht, Prescription Drug State Information, at http://www.gil.house.gov/issues/
pdrugs/ stateinfo.htm (last visited Mar. 5, 2005) (listing states that have or are
proceeding to implement programs to import drugs).
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milligram tablets of tamoxifen from the Canadian pharmacies for
about $33, including shipping, as compared to $66 as listed on the
146
website of a large U.S. pharmacy chain. In contrast, if purchased
as a prescription from a Canadian pharmacy, the brand name drug
Claritin would be more expensive than purchasing the medication
147
over-the-counter in the United States.
Accordingly, it is
important for the consumer to compare both prescription
medicine prices between the Canadian pharmacy and the
American pharmacy and also among Canadian pharmacies and
among American pharmacies because prices vary.
To help consumers, RxConnect not only provides information
on Canadian pharmacies, but also includes information on state
prescription medicine programs for low-income people, a statesponsored information line that provides assistance in navigating
the various free prescription medicine programs run by the
pharmaceutical companies and the new Medicare drug discount
cards, how to be a smart prescription medicine shopper, and
148
various strategies on how to reduce prescription medicine costs.
Of the prescription medicines initially listed on RxConnect
about eighty-five percent are less expensive in Canada than in the
United States, with the remaining fifteen percent being more
149
expensive in Canada.
The statistics on the prescription
medicines being purchased through RxConnect indicate that
consumers are aware of these price differences as the prescription
medicines most commonly purchased are those with the greatest
150
savings compared to the United States prices.
Most of the
prescription medicines that are more expensive in Canada will be
removed from RxConnect in future updates as they offer limited
value to the consumer and are rarely ordered.
Through January of 2005, RxConnect had 174,599 website

146. Information provided by Cody Wiberg, Pharmacy Program Manager,
Minnesota Department of Human Services (on file with author). Tamoxifen can
be purchased for $42.98, $35.38 or $23.87 from various Canadian pharmacies. Id.
The same dosage is listed on the Walgreens website for $65.99. Walgreens.com,
Tamoxifen, 10 mg. tablets, at http://www.walgreens.com/library/finddrug/
druginfo1.jhtml?id=15379 (last visited Jan. 26, 2005).
147. Wiberg, supra note 146.
148. Website of the Minnesota RxConnect Program, Minnesota Department of
Human Services, at http://www.minnesotarxconnect.com (last visited Jan. 26,
2005).
149. See id.
150. Id.
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151

visits and over 9000 orders have been filled.
The assumption
when the program was established was that the people most likely
to take advantage of the program were those individuals who were
already purchasing their prescription medicines from unknown
mail-order or other discount pharmacies. Minnesota RxConnect
was established to provide those individuals with information on
Canadian pharmacies that had been inspected and had agreed to
follow certain safe practices.
V. ADVANTAGE-MEDS
Phase II of the Minnesota plan provides access to low-cost,
Canadian prescription medicines for Minnesota state employees.
152
Advantage-Meds
Advantage-Meds was launched in May 2004.
built on the work done in setting up and choosing vendors for
RxConnect. One of the RxConnect pharmacies was selected by the
Minnesota Department of Employee Relations (DOER) to work
with its health plan in establishing a state employee program.
DOER identified a list of forty-seven prescription medicines
that would provide substantial savings to both the state and its
employees if employees purchase them from the Canadian
153
pharmacy.
The employee benefits if he or she orders a ninetyday supply of a selected prescription medicine because the state
154
waives the employee’s $15 per prescription co-pay.
This could
result in up to a $180 per year per prescription savings for the
155
The state projects that its savings will be about $1.4
employee.
156
million per year.
The process for ordering is similar to the process for
RxConnect, except that the state health plan makes payment
directly to the Canadian pharmacy rather than having the
employee make the payment and then seek reimbursement from
the plan. At the end of 2004, more than 1800 state employees had
signed up for the program and more than 3100 prescriptions have
151. Id.
152. Press Release, Tim Pawlenty, Governor of Minnesota, Governor Pawlenty
Launches Phase Two of Rx Drug Importation: State Employee Website (May 13,
2003) (on file with author).
153. Id.
154. State of Minnesota, Department of Employee Relations, Canadian
Prescription Drug Plan for Minnesota State Employees and Dependents, available at
http://www.advantage-meds.state.mn.us/Factsheet.pdf (last visited Jan. 26, 2005).
155. Id.
156. Id.
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VI. PHASE III PILOT PROJECT
Although DHS has had exploratory discussions with the FDA
regarding a pilot program in Minnesota that would allow the
inclusion of Minnesota pharmacies in the ordering of prescription
medicines from Canada, no definitive agreement has been
reached.
VII. CONCLUSION
Governor Pawlenty has recognized the reality that many
Minnesotans purchase prescription medicines from unknown mailorder pharmacies that hold themselves out as legitimate operators
selling Canadian approved prescription medicines.
This
recognition led to the launch of RxConnect which is consistent
with federal law and the duties of the state to provide for the safety
of its citizens. Minnesota provided for the safety of its citizens by
inspecting Canadian pharmacies to ensure their legitimacy and
compliance with applicable laws and safe operating procedures and
then shared that information with its citizens through RxConnect.
More specifically, Minnesota took steps to ensure that prescription
medicines ordered from the RxConnect pharmacies were approved
for distribution in Canada. Further, Minnesota verified that the
RxConnect pharmacies were licensed and that the professionals
who worked for them were licensed and in good standing. In other
words, through RxConnect, Governor Pawlenty put a program in
place to provide Minnesota consumers who choose to purchase
prescription medicines from Canada access to medicines that are,
in the words of the FDA, “safe and effective.”
Minnesota has been a leader in addressing the challenges of
keeping prescription medicines affordable for Minnesotans and
controlling overall health care costs. Sometimes these challenges
seem daunting, even impossible, but in the words of Franklin
Delano Roosevelt, as quoted by Governor Pawlenty at a
congressional hearing on importation, “It is common sense to take
a method and try it; if it fails, admit it frankly and try another. But

157. State of Minnesota, Department of Employee Relations, Advantage Meds
Activity (Jan. 2004), available at http://www.advantage-meds.state.mn.us/
Activity.pdf (last visited Jan. 26, 2005).
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158

above all, try something.”
Minnesota was the first state in the
nation to establish a program such as RxConnect. Minnesota was
also the first state in the nation to implement a program for its
employees to purchase lower cost medications from Canada. From
the Pawlenty Administration’s perspective, Minnesota RxConnect
and Advantage-Meds have proven to be effective in helping
Minnesotans, and state government, save on the cost of highquality, safe prescription medicines. Now it is time to try
something else, such as Phase III of Governor Pawlenty’s plan,
because a more widespread utilization of Canadian-supplied
prescription medicines, through wholesale importation by
Minnesota pharmacies, would benefit Minnesota consumers and
the state’s health care costs.

158. Tim Pawlenty, Governor of Minnesota, Testimony to the Congressional
Prescription Drug Access Coalition hearing in Boston, MA (Oct. 28, 2003)
(transcript available at http://www.governor.state.mn.us/Tpaw_View_DF_Article.
asp?artid=654).
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